🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalEU EMA compounding guidance — May 2025

EU EMA compounding guidance — May 2025

JakeBK_lifts Mon, Apr 13, 2026 at 8:06 PM 4 replies 548 viewsPage 1 of 1
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
Apr 13, 2026 at 8:06 PM#1

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within weeks of each other.

What would genuinely help is knowing what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

Numbers rather than impressions, if you have them.

17 12TrialTracker_MD, JennaRN, LabKate and 14 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Apr 13, 2026 at 9:06 PM#2

Short answer first, then the reasoning. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

16 11VanRx_Mike, steve_okc, dave_SLC and 13 others
Reply Quote Save Share Report
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Apr 13, 2026 at 10:06 PM#3
kate.chem said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreeing with kate.chem, and the qualification matters more than the agreement. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

Last edited: Apr 14, 2026 at 12:06 AM
15 10DoseLogDan, SleepFixSam, PurityPaulOR and 12 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Apr 13, 2026 at 11:06 PM#4
JakeBK_lifts said:
Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Can confirm the pattern JakeBK_lifts describes. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Apr 14, 2026 at 2:06 AM
14 9LarryQC_SD, wanda_boise, NurseAsh_DET and 11 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Apr 14, 2026 at 4:50 AM#5

From the other side of the consultation, briefly.

Compounding pharmacy licensing verification for compounded supply: before ordering, verify your pharmacy's credentials:

  1. State Board of Pharmacy license — check on your state BOP website
  2. FDA registration (for 503B) — check on fda.gov
  3. DEA registration if handling controlled substances
  4. PCAB accreditation — voluntary but demonstrates commitment to quality
  5. USP <797>/<800> compliance for sterile compounding

This takes 10 minutes of research and could save you from receiving substandard or unsafe medication.

13 8sarah_nash92, FitDadDave, RunnerRach and 10 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register